This new study challenges long-standing beliefs about autism
Prior research has shown that people with autism spectrum disorder (ASD) often experience difficulties recognizing faces and even emotional responses. This, many speculate, is what leads individuals with autism to exhibit social communication problems.
But the problem with this understanding is that we've never had any clear evidence of how a brain affected by autism perceives the human face and body. This has left us with plenty of questions, but a new study led by Waseda University in Japan could prove this theory wrong and completely change everything we thought we know about how individuals with ASD perceive the faces and bodies of those around them.
Today's Top Deals
XGIMI Prime Day deals feature the new MoGo 4 and up to 42% off smart projectors
Best deals: Tech, laptops, TVs, and more sales
Best Ring Video Doorbell deals
Challenging long-held beliefs
The belief that individuals with ASD often suffer from social communication issues that are driven by how their brains perceive others is a long-standing one. However, as noted above, there's never been any scientific proof to back it up. In this new study from Waseda University, scientists took detailed neuroimages of 23 adults with ASD and compared them to the neuroimages of 23 typically developing (TD) adults. The results were not as different as expected.
The researchers note that when looking at the images, they expected to see differences in the lateral occipitotemporal cortex (LOTC). This region of the brain is known to represent the visual information the brain processes to perceive the human body. Until now, it was assumed that individuals with autism, or ASD, would have that information clustered in a different way within their LOTC.
However, that isn't the case at all. When looking at the data, the researchers found that individuals in the ASD and TD groups all showed similar structures of activations for their LOTCs. This could disprove the theory that individuals with ASD perceive the human body differently, thus leading to other social communication issues. The researchers also note that there were no significant differences in the size or strength of the activation of the LOTC in either group.
'These results suggest that adults with autism perceive visual body information in much the same way as neurotypical adults,' Professor Hirotaka Kurihara shared in a statement. '[This] challenges long-standing assumptions that differences in body-related perception contribute to social difficulties in ASD.'
To double-check the results, the researchers also looked at whether brain patterns could be linked to individual differences. However, they also found no strong connections in this area, either. So, while it is true that individuals with ASD might struggle to read emotions or intentions based on expressions and gestures, that struggle does not seem to be tied to how their brains perceive the human body or face, which could help further research dig deeper into what the actual underlying cause is.
We're still a long way from truly understanding autism and the overall affect it has on the individuals affected by it. But researchers are working hard to learn more. We've also seen some pretty amazing breakthroughs in AI development, including an AI that can detect autism just by looking at how you hold objects.
More Top Deals
Memorial Day security camera deals: Reolink's unbeatable sale has prices from $29.98
See the
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11 minutes ago
- Yahoo
3 Asian Penny Stocks With Market Caps Below US$10B
Amid a backdrop of favorable trade deals and positive market sentiment, Asian markets have been buoyed by renewed optimism. This environment provides a fertile ground for penny stocks, which, despite the outdated terminology, continue to offer intriguing opportunities for investors. These stocks typically represent smaller or newer companies that can combine affordability with growth potential when supported by strong financials and fundamentals. Top 10 Penny Stocks In Asia Name Share Price Market Cap Financial Health Rating Food Moments (SET:FM) THB4.02 THB3.97B ★★★★★☆ Lever Style (SEHK:1346) HK$1.46 HK$921.19M ★★★★★★ TK Group (Holdings) (SEHK:2283) HK$2.51 HK$2.09B ★★★★★★ CNMC Goldmine Holdings (Catalist:5TP) SGD0.485 SGD196.57M ★★★★★☆ Goodbaby International Holdings (SEHK:1086) HK$1.20 HK$2B ★★★★★★ T.A.C. Consumer (SET:TACC) THB4.60 THB2.76B ★★★★★★ China Sunsine Chemical Holdings (SGX:QES) SGD0.70 SGD667.37M ★★★★★★ Yangzijiang Shipbuilding (Holdings) (SGX:BS6) SGD2.54 SGD10B ★★★★★☆ Ekarat Engineering (SET:AKR) THB0.95 THB1.4B ★★★★★★ Livestock Improvement (NZSE:LIC) NZ$0.95 NZ$135.23M ★★★★★★ Click here to see the full list of 970 stocks from our Asian Penny Stocks screener. Let's take a closer look at a couple of our picks from the screened companies. Alibaba Health Information Technology Simply Wall St Financial Health Rating: ★★★★★★ Overview: Alibaba Health Information Technology Limited is an investment holding company that operates in pharmaceutical direct sales, pharmaceutical e-commerce platforms, and healthcare and digital services in Mainland China and Hong Kong, with a market cap of approximately HK$77.99 billion. Operations: The company's revenue from the distribution and development of pharmaceutical and healthcare products is CN¥30.60 billion. Market Cap: HK$77.99B Alibaba Health Information Technology has demonstrated significant earnings growth, with a notable increase of 62.1% over the past year, surpassing its five-year average of 52.2%. The company reported revenues of CN¥30.60 billion for the fiscal year ending March 31, 2025, and improved net profit margins to 4.7%. Despite a one-off loss impacting recent results, Alibaba Health remains debt-free and trades below its estimated fair value by approximately 12.6%. Its short-term assets comfortably cover both short- and long-term liabilities, although the board's average tenure is relatively inexperienced at three years. Click here and access our complete financial health analysis report to understand the dynamics of Alibaba Health Information Technology. Gain insights into Alibaba Health Information Technology's future direction by reviewing our growth report. Shanghai Trendzone Holdings GroupLtd Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: Shanghai Trendzone Holdings Group Co., Ltd, with a market cap of CN¥3.74 billion, offers integrated solutions in design, construction, production, and services both in China and internationally. Operations: No specific revenue segments have been reported for Shanghai Trendzone Holdings Group Co., Ltd. Market Cap: CN¥3.74B Shanghai Trendzone Holdings Group Co., Ltd, with a market cap of CN¥3.74 billion, has shown some financial resilience despite being unprofitable. Its short-term assets of CN¥1.3 billion comfortably cover both short- and long-term liabilities, indicating solid liquidity management. The company's debt to equity ratio has improved over five years to 42.5%, suggesting prudent debt management, while its net debt to equity ratio is satisfactory at 35.3%. However, the firm remains unprofitable with a negative return on equity of -9.78% and faces high share price volatility alongside less than one year of cash runway based on current free cash flow trends. Dive into the specifics of Shanghai Trendzone Holdings GroupLtd here with our thorough balance sheet health report. Assess Shanghai Trendzone Holdings GroupLtd's previous results with our detailed historical performance reports. Leo Group Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: Leo Group Co., Ltd. operates in China through its subsidiaries, focusing on the research, development, manufacture, and sale of pumps and garden machinery products with a market cap of CN¥24.94 billion. Operations: No specific revenue segments are reported for Leo Group Co., Ltd. Market Cap: CN¥24.94B Leo Group Co., Ltd. has a market cap of CN¥24.94 billion and operates in China, focusing on pumps and garden machinery products. Despite having more cash than total debt, its operating cash flow covers only 12.3% of the debt, indicating potential liquidity concerns. The company's net profit margin decreased to 0.4% from 5.6% last year, with earnings declining by 33.2% annually over five years due to a significant one-off loss of CN¥388.7M affecting recent results as of March 2025. While short-term assets exceed liabilities significantly, the dividend yield remains poorly covered by earnings or free cash flows. Unlock comprehensive insights into our analysis of Leo Group stock in this financial health report. Evaluate Leo Group's historical performance by accessing our past performance report. Key Takeaways Embark on your investment journey to our 970 Asian Penny Stocks selection here. Looking For Alternative Opportunities? The latest GPUs need a type of rare earth metal called Neodymium and there are only 25 companies in the world exploring or producing it. Find the list for free. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include SEHK:241 SHSE:603030 and SZSE:002131. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data
Fox News
3 hours ago
- Fox News
Forget 10,000 steps — research reveals the real number you need for better health
You may not need as many steps as you thought. Ten thousand steps per day has been widely recommended as the standard benchmark for physical activity — but a new study suggests that just 7,000 could be enough to boost essential health markers. Researchers from the University of Sydney conducted a review of 57 studies spanning more than 10 countries, which tracked participants' steps and health outcomes. SIMPLE JAPANESE FITNESS TREND COULD ADD 7 YEARS TO LIFE EXPECTANCY, EXPERTS SAY Led by Professor Melody Ding from the School of Public Health, the team looked at how different daily step counts impacted the risk of dying from heart disease and cancer, as well as the risk of developing cancer, type 2 diabetes, dementia and depression, according to a university press release. They found that walking at least 7,000 steps a day was linked to improvement in eight major health outcomes, including heart disease, dementia and depressive symptoms. "Any increase in daily steps, even modest ones like 4,000 steps, delivers health benefits compared to very low activity levels," Ding told Fox News Digital. "When possible, targeting around 7,000 steps per day can substantially reduce risks for many chronic diseases and adverse health outcomes." "Even small increases in step counts, such as increasing from 2,000 to 4,000 steps a day, are associated with significant health gain." Higher step counts beyond 7,000 may add extra benefits, but the improvement rate slows, she noted. The results were published in The Lancet Public Health journal. In particular, the researchers found that walking 7,000 steps a day reduced the risk of death by 47%, almost exactly the same as 10,000 steps. That same step benchmark was also linked to a 38% reduced risk of dementia and a 22% reduced risk of type 2 diabetes, both only slightly lower than the benefit of 10,000 steps, the release stated. "Significant health improvements" were reported when people increased from 2,000 steps per day to anywhere between 5,000 and 7,000. "Aiming for 7,000 steps is a realistic goal based on our findings, which assessed health outcomes in a range of areas that hadn't been looked at before," said Professor Ding in the release. "However, for those who cannot yet achieve 7,000 steps a day, even small increases in step counts, such as increasing from 2,000 to 4,000 steps a day, are associated with significant health gain." For those who are already very active and consistently hitting 10,000+ steps, Ding said, "keep it up — there's no need to cut back." The researchers also noted that stepping doesn't need to happen all at once or require intentional exercise. "Everyday movements count — like getting off the bus a stop earlier or choosing stairs over elevators," Ding advised. "Small, incidental bouts throughout the day add up and contribute to health. Embrace opportunities to move more in practical, enjoyable ways." There were some limitations in the study, the researchers noted. "For some outcomes, we have a small number of studies," Ding told Fox News Digital. There are also some study-level biases, she said. "For example, people who are already unwell will take fewer steps because of their health conditions," Ding said. "And while there is an indication that the dose-response may be different for older adults, we didn't have enough data for all outcomes to explore it." It's also important to note that while walking offers great health benefits, it is not a complete "package" in itself, she noted. "Everyday movements count — like getting off the bus a stop earlier or choosing stairs over elevators." "Try to also incorporate strength training and mobility exercise into a weekly routine for more complete health benefits." In next steps, the researchers plan to use these findings to shape future physical activity guidelines. For more Health articles, visit Experts recommend that future studies of step count impacts should focus on variations for age, health status and region, the release stated. "Our research helps to shift the focus from perfection to progress," Ding said. "Even small increases in daily movement can lead to meaningful health improvements."
Yahoo
5 hours ago
- Yahoo
Millions of people are suffering from brain fog. A new study will find out why
Millions of people who recover from infections like COVID-19, influenza and glandular fever are affected by long-lasting symptoms. These include chronic fatigue, brain fog, exercise intolerance, dizziness, muscle or joint pain and gut problems. And many of these symptoms worsen after exercise, a phenomenon known as post-exertional malaise. Medically the symptoms are known as myalgic encephalomyelitis or chronic fatigue syndrome (ME/CFS). The World Health Organization classifies this as a post viral fatigue syndrome, and it is recognised by both the WHO and the United States Centers for Disease Control and Prevention as a brain disorder. Experiencing illness long after contracting an infection is not new, as patients have reported these symptoms for decades. But COVID-19 has amplified the problem worldwide. Nearly half of people with ongoing post-COVID symptoms – a condition known as long-COVID – now meet the criteria for ME/CFS. Since the start of the pandemic in 2020, it is estimated that more than 400 million people have developed long-COVID. To date, no widely accepted and testable mechanism has fully explained the biological processes underlying long-COVID and ME/CFS. Our work offers a new perspective that may help close this gap. Our research group studies blood and the cardiovascular system in inflammatory diseases, as well as post-viral conditions. We focus on coagulation, inflammation and endothelial cells. Endothelial cells make up the inner layer of blood vessels and serve many important functions, like regulating blood clotting, blood vessel dilation and constriction, and inflammation. Our latest review aims to explain how ME/CFS and long-COVID start and progress, and how symptoms show up in the body and its systems. By pinpointing and explaining the underlying disease mechanisms, we can pave the way for better clinical tools to diagnose and treat people living with ME/CFS and long-COVID. What is endothelial senescence? In our review, our international team proposes that certain viruses drive endothelial cells into a half-alive, 'zombie-like' state called cellular senescence. Senescent endothelial cells stop dividing, but continue to release molecules that awaken and confuse the immune system. This prompts the blood to form clots and, at the same time, prevent clot breakdown, which could lead to the constriction of blood vessels and limited blood flow. By placing 'zombie' blood-vessel cells at the centre of these post-viral diseases, our hypothesis weaves together microclots, oxygen debt (the extra oxygen your body needs after strenuous exercise to restore balance), brain-fog, dizziness, gut leakiness (a digestive condition where the intestinal lining allows toxins into the bloodstream) and immune dysfunction into a single, testable narrative. From acute viral infection to 'zombie' vessels Viruses like SARS-CoV-2, Epstein–Barr virus, HHV-6, influenza A, and enteroviruses (a group of viruses that cause a number of infectious illnesses which are usually mild) can all infect endothelial cells. They enable a direct attack on the cells that line the inside of blood vessels. Some of these viruses have been shown to trigger endothelial senescence. Multiple studies show that SARS-CoV-2 (the virus which causes COVID-19 disease) has the ability to induce senescence in a variety of cell types, including endothelial cells. Viral proteins from SARS-CoV-2, for example, sabotage DNA-repair pathways and push the host cell towards a senescent state, while senescent cells in turn become even more susceptible to viral entry. This reciprocity helps explain why different pathogens can result in the same chronic illness. Influenza A, too, has shown the ability to drive endothelial cells into a senescent, zombie-like state. What we think is happening We propose that when blood-vessel cells turn into 'zombies', they pump out substances that make blood thicker and prone to forming tiny clots. These clots slow down circulation, so less oxygen reaches muscles and organs. This is one reason people feel drained. During exercise, the problem worsens. Instead of the vessels relaxing to allow adequate bloodflow, they tighten further. This means that muscles are starved of oxygen and patients experience a crash the day after exercise. In the brain, the same faulty cells let blood flow drop and leak, bringing on brain fog and dizziness. In the gut, they weaken the lining, allowing bits of bacteria to slip into the bloodstream and trigger more inflammation. Because blood vessels reach every corner of the body, even scattered patches of these 'zombie' cells found in the blood vessels can create the mix of symptoms seen in long-COVID and ME/CFS. Immune exhaustion locks in the damage Some parts of the immune system kill senescent cells. They are natural-killer cells, macrophages and complement proteins, which are immune molecules capable of tagging and killing pathogens. But long-COVID and ME/CFS frequently have impaired natural-killer cell function, sluggish macrophages and complement dysfunction. Senescent endothelial cells may also send out a chemical signal to repel immune attack. So the 'zombie cells' actively evade the immune system. This creates a self-sustaining loop of vascular and immune dysfunction, where senescent endothelial cells persist. In a healthy person with an optimally functioning immune system, these senescent endothelial cells will normally be cleared. But there is significant immune dysfunction in ME/CFS and long-COVID, and this may enable the 'zombie cells' to survive and the disease to progress. Where the research goes next There is a registered clinical trial in the US that is investigating senescence in long-COVID. Our consortium is testing new ways to spot signs of ageing in the cells that line our blood vessels. First, we expose healthy endothelial cells in the lab to blood from patients to see whether it pushes the cells into a senescent, or 'zombie,' state. At the same time, we are trialling non‑invasive imaging and fluorescent probes that could one day reveal these ageing cells inside the body. In selected cases, tissue biopsies may later confirm what the scans show. Together, these approaches aim to pinpoint how substances circulating in the blood drive cellular ageing and how that, in turn, fuels disease. Our aim is simple: find these ageing endothelial cells in real patients. Pinpointing them will inform the next round of clinical trials and open the door to therapies that target senescent cells directly, offering a route to healthier blood vessels and, ultimately, lighter disease loads. Burtram C. Fielding is Dean Faculty of Sciences and Professor in the Department of Microbiology, Stellenbosch University This article is republished from The Conversation under a Creative Commons license. Read the original article.
